Details of the Drug Combination

General Information of Drug Combination (ID: DC9SYIS)

• Drug Combination Name: Trimethobenzamide + BHV-0223
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Trimethobenzamide (DMPP4DT): Small molecular drug
  BHV-0223 (DMBLM5H): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 1.91
  Bliss Independence Score: 1.91
  Loewe Additivity Score: 8.7
  LHighest Single Agent (HSA) Score: 8.71

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] Trimethobenzamide FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)